/biz/ - Business & Finance

>>1363144
forgot muh link
http://www.insidermonkey.com/blog/answering-two-most-important-questions-surrounding-ampio-pharmaceuticals-inc-ampe-462760/

>Ampio Pharmaceuticals Inc (NYSEMKT:AMPE) has recently reported topline from its PIVOT trial and the stock lost over 60% on the announcement last Thursday.

>What are the chances of the FDA giving its candidate the green light, and by proxy, what are the chances an allocation at the current discounted price would turn out to be a rewarding exposure?

>The first, the chances look OK. The FDA will be fully aware of the limited options grade 4 KL patients have available to them right now, and it wouldn’t be the first time the agency gives a drug the green light despite low efficacy. In short, what’s it got to lose by doing so? To answer the second question, again, pretty good. Of course, if Ampio Pharmaceuticals Inc (NYSEMKT:AMPE) goes for the trimmed down target population, but analysis suggest late stage OA still occurs in around 10% of healthy weight US adults over 60 and up to 35% in obese US adults over 60, so there’s still plenty of patients to go at.

>The company is set to discuss the findings on a conference call early next week, so we might get a bit more info then. Beyond that, a discussion with the FDA, and the resulting actions from that discussion, look to be the major near term milestones.

Might be worth further research and watch-listing.